DK0635264T3 - Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler - Google Patents

Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler

Info

Publication number
DK0635264T3
DK0635264T3 DK94304441.2T DK94304441T DK0635264T3 DK 0635264 T3 DK0635264 T3 DK 0635264T3 DK 94304441 T DK94304441 T DK 94304441T DK 0635264 T3 DK0635264 T3 DK 0635264T3
Authority
DK
Denmark
Prior art keywords
phenyl
aroylbenzothiazepines
estrogenic
hypoglycemic agents
triarylethylenes
Prior art date
Application number
DK94304441.2T
Other languages
English (en)
Inventor
George Joseph Cullinan
Terence T Yen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0635264T3 publication Critical patent/DK0635264T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK94304441.2T 1993-06-24 1994-06-20 Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler DK0635264T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8221893A 1993-06-24 1993-06-24

Publications (1)

Publication Number Publication Date
DK0635264T3 true DK0635264T3 (da) 1997-10-20

Family

ID=22169806

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94304441.2T DK0635264T3 (da) 1993-06-24 1994-06-20 Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler

Country Status (23)

Country Link
US (1) US5567713A (da)
EP (1) EP0635264B1 (da)
JP (1) JP2886453B2 (da)
KR (1) KR100325034B1 (da)
CN (1) CN1086576C (da)
AT (1) ATE157869T1 (da)
AU (1) AU669627B2 (da)
CA (1) CA2126400A1 (da)
CZ (1) CZ285522B6 (da)
DE (1) DE69405491T2 (da)
DK (1) DK0635264T3 (da)
ES (1) ES2105525T3 (da)
GR (1) GR3025315T3 (da)
HU (1) HUT75253A (da)
IL (1) IL110052A (da)
NO (1) NO312398B1 (da)
NZ (1) NZ260790A (da)
PH (1) PH30490A (da)
PL (1) PL181025B1 (da)
RU (1) RU2132682C1 (da)
TW (1) TW275584B (da)
UA (1) UA34441C2 (da)
ZA (1) ZA944377B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
CA2249406A1 (en) * 1996-03-19 1997-09-25 Eli Lilly And Company Synthesis of 3-¬4-(2-aminoethoxy)-benzoyl|-2-aryl-6-hydroxy-benzo¬b|thiophenes
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN1390126B (zh) 1999-07-06 2012-06-13 恩多研究公司 选择性雌激素受体调节剂在制备用于治疗或降低肥胖症发展危险性的药物中的用途
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
WO2011007882A1 (ja) * 2009-07-16 2011-01-20 国立大学法人九州大学 インスリン産生細胞誘導剤、グルコース取込み促進剤および糖尿病または糖尿病合併症の治療薬
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
BE637389A (da) * 1962-09-13
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4323707A (en) * 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4970237A (en) * 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE69023906T2 (de) * 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤

Also Published As

Publication number Publication date
EP0635264B1 (en) 1997-09-10
NO942363L (no) 1994-12-27
JPH0748252A (ja) 1995-02-21
NO942363D0 (da) 1994-06-21
IL110052A0 (en) 1994-10-07
NZ260790A (en) 1997-06-24
AU669627B2 (en) 1996-06-13
CZ285522B6 (cs) 1999-08-11
CZ152094A3 (en) 1995-03-15
CN1086576C (zh) 2002-06-26
PH30490A (en) 1997-05-28
NO312398B1 (no) 2002-05-06
US5567713A (en) 1996-10-22
CN1100933A (zh) 1995-04-05
RU94022479A (ru) 1997-03-20
DE69405491D1 (de) 1997-10-16
EP0635264A3 (en) 1995-04-12
ES2105525T3 (es) 1997-10-16
RU2132682C1 (ru) 1999-07-10
JP2886453B2 (ja) 1999-04-26
PL181025B1 (pl) 2001-05-31
TW275584B (da) 1996-05-11
UA34441C2 (uk) 2001-03-15
ATE157869T1 (de) 1997-09-15
EP0635264A2 (en) 1995-01-25
KR950000145A (ko) 1995-01-03
ZA944377B (en) 1995-12-20
HU9401904D0 (en) 1994-09-28
AU6488294A (en) 1995-01-05
CA2126400A1 (en) 1994-12-25
IL110052A (en) 2001-04-30
HUT75253A (en) 1997-05-28
PL303937A1 (en) 1995-01-09
GR3025315T3 (en) 1998-02-27
KR100325034B1 (ko) 2002-08-21
DE69405491T2 (de) 1998-02-19

Similar Documents

Publication Publication Date Title
DK0635264T3 (da) Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
NO932650L (no) Forbedringer vedroerende benzotio-fener
TW263423B (da)
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
EP0359260A3 (en) The use of inositoltrisphosphate for the preparing of a medicament against abnormal levels of lipoproteins
BR9201083A (pt) Composto,estereoisomero,formulacao farmaceutica e processo para a preparacao de um composto
IL105475A0 (en) Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis
HUT50787A (en) Process for producing pharmaceutical compositions comprising 4-aryl-4-piperidine-, pyrrolidine- or hexahydroazepincarbinol derivatives or heterocyclic analogs thereof as active ingredient and process for producing the new compounds
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
FI914285A0 (fi) Valmiste käsien puhdistamiseen ja/tai desinfioimiseen, jota valmistetta voidaan käyttää saippuanannostelijalla
ES2067621T3 (es) Procedimiento para la preparacion de compuestos molusquicidas de 2,4,5-tribromopirrol-3-carbonitrilo.
BR8902384A (pt) Politioureias,processo para a preparacao das mesmas
IT1239610B (it) Metodo operativo per un filatoio.
BR8902385A (pt) Politioureias,processo para a preparacao das mesmas